SCHEMBL13762197

SCHEMBL13762197

COCCNc1cccc(C(C)(C)C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.51
▸ RXFP1 Q9HBX9 2/20 0.51
▸ HDAC3 O15379 1/20 0.43
▸ HDAC8 Q9BY41 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ KCNH3 Q9ULD8 2/20 0.43
▸ ICMT O60725 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MAPT P10636 3/20 0.42
▸ HTT P42858 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ P2RX1 P51575 1/20 0.39
▸ KCNJ6 P48051 1/20 0.39
▸ KCNJ5 P48544 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888914 0.81 HRH3 (0.55) HRH3RXFP1HDAC3HDAC8HDAC6
SCHEMBL29198050 0.81 HRH3 (0.55) HRH3RXFP1HDAC3HDAC8HDAC6
SCHEMBL14065406 0.79 HRH3 (0.54) HRH3HDAC3HDAC8HDAC6ICMT
SCHEMBL14065443 0.79 HRH3 (0.54) HRH3HDAC3HDAC8HDAC6ICMT
SCHEMBL13762190 0.79 MAPT (0.49) HRH3KCNH3SMN1; SMN2MAPTHTT
SCHEMBL9788107 0.78 HRH3 (0.51) HRH3RXFP1HDAC3HDAC8HDAC6
SCHEMBL23406283 0.78 HDAC3 (0.52) RXFP1HDAC3HDAC8HDAC6SMN1; SMN2
SCHEMBL14149932 0.78 HRH3 (0.52) HRH3HDAC3HDAC8HDAC6KCNH3
SCHEMBL7221434 0.77 MEN1 (0.49) RXFP1KCNH3ICMTSMN1; SMN2MAPT
SCHEMBL6995577 0.77 MAPT (0.71) RXFP1KCNH3ICMTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557110-B2 MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine TEIJIN PHARMA LIMITED (JP) 2009-07-07 — — US disclosed
Send feedback